Irvine, California-based Inari ... pullback 10:53 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory AbbVie cuts 2024 profit forecast on acquisition expenses 10:46 PM UTC · Updated ...

While very early, the results are encouraging, according to Ray Wang, a specialist in metabolic disorders at the University of California, Irvine ... licensing deal with AbbVie for an AAV8 ...

Irvine, CA, USA Pimavanserin is a selective inverse agonist–antagonist of the 5-HT2A receptor that is approved in the USA for treatment of hallucinations and delusions in Parkinson's disease. 1 ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

AbbVie returned to round out the top 10 list, with just under $118 million spent on TV commercials for Vraylar, which is used to treat bipolar disorder and depression and which had previously sat ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Louis Navellier is a prominent American investor, author, and financial analyst ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been underperforming ...